Evidence map›Paper›PMID 33864107›Full record

ReviewAbdominal radiology (New York)2021

Therapies for hepatocellular carcinoma: overview, clinical indications, and comparative outcome evaluation. Part two: noncurative intention.

Joseph H Yacoub, David Mauro, Andrew Moon, Aiwu R He, Mustafa R Bashir, Christine C Hsu, Thomas M Fishbein, Lauren M B Burke

Abstract readReview
PubMed Publisher
In one paragraph

Review in Abdominal radiology (New York), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Joseph H YacoubDepartment of Radiology, Georgetown University, Washington DC, USA. joeyacoub@gmail.com.ORCID http://orcid.org/0000-0002-7831-1680
David MauroDepartment of Radiology, University of North Carolina School of Medicine, 101 Manning Drive, CB 7510, Chapel Hill, NC, 27514, USA.
Andrew MoonDepartment of Radiology, University of North Carolina School of Medicine, 101 Manning Drive, CB 7510, Chapel Hill, NC, 27514, USA.
Aiwu R HeDepartment of Medicine, Georgetown University, Washington DC, USA.
Mustafa R BashirDepartment of Radiology and Medicine (Gastroenterology), Duke University School of Medicine, Durham, NC, 27710, USA.
Christine C HsuGeorgetown University, Medstar Georgetown Transplant Institute, Washington DC, USA.
Thomas M FishbeinGeorgetown University, Medstar Georgetown Transplant Institute, Washington DC, USA.
Lauren M B BurkeDepartment of Radiology, University of North Carolina School of Medicine, 101 Manning Drive, CB 7510, Chapel Hill, NC, 27514, USA. lauren_burke@med.unc.edu.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Locoregional therapies can be offered to hepatocellular carcinoma patients as a bridge to transplant, to downstage disease burden for transplant eligibility, or for disease control to prolong survival. Systemic therapies also play a large role in HCC treatment, occasionally in conjunction with other methods. This manuscript reviews the various treatment options for HCC with a historically noncurative intent.

Indexed as

Carcinoma, HepatocellularLiver NeoplasmsHumansIntentionChemoembolizationHepatocellular carcinomaLocoregional therapiesRadioembolizationStereotactic body radiotherapySystemic therapies

Identifiers

PMID33864107

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.